News Articles Tagged: CAL-101

The Role of GS-1101 (Idelalisib) in Targeting Cancer Cell Survival Pathways

Examine the crucial role of GS-1101 (Idelalisib) in disrupting cancer cell survival pathways by inhibiting PI3K-delta, offering a focused therapeutic strategy.

The Power of Precision: Understanding Idelalisib (CAL-101) and PI3K-Delta Inhibition

Discover the precision of Idelalisib (CAL-101), a targeted PI3K-delta inhibitor, and its crucial role in selectively targeting cancer cells, offering a more refined approach to treatment.

Idelalisib in Clinical Trials: Advancing Treatment for Hematologic Malignancies

Explore the progress and impact of Idelalisib (CAL-101) in clinical trials, focusing on its efficacy and safety in treating various hematologic malignancies and its role in modern oncology.

The Science Behind Idelalisib (GS-1101): Targeting PI3K-Delta for Cancer Therapy

Delve into the scientific underpinnings of Idelalisib (GS-1101), exploring its precise PI3K-delta inhibition and its impact on the PI3K pathway in the context of cancer treatment.

CAL-101 (Idelalisib): A Targeted Approach to Treating Refractory Lymphoma and Leukemia

Learn how CAL-101, also known as Idelalisib or GS-1101, is revolutionizing the treatment of refractory non-Hodgkin's lymphoma and chronic lymphocytic leukemia through its selective PI3K-delta inhibition.

Understanding the PI3K Pathway: A Deep Dive into Idelalisib's Mechanism of Action

Explore the intricacies of the PI3K pathway and how Idelalisib (CAL-101) selectively inhibits PI3K-delta, offering a targeted approach to treating hematologic malignancies. Learn about its clinical significance and potential.